Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders (2011 - 2026)

Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$40.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 138.84% year-over-year to -$40.2 million in Q1 2026; TTM through Mar 2026 was -$147.4 million, a 11.72% decrease from a year earlier, with the FY2025 full-year figure at -$124.0 million, up 4.63% from the prior year.
• Net Income towards Common Stockholders improved to -$40.2 million in Q1 2026 per TNXP's latest filing, from -$46.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$14.2 million in Q3 2024 and bottomed at -$78.8 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$28.3 million (2025), against an average of -$31.1 million.
• Across the five-year window, Net Income towards Common Stockholders sank 177.81% in 2024 and jumped 64.11% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$34.1 million in 2022, then increased by 19.84% to -$27.3 million in 2023, then rose by 19.08% to -$22.1 million in 2024, then slumped by 112.19% to -$46.9 million in 2025, then grew by 14.32% to -$40.2 million in 2026.
• Per Business Quant, the three latest TNXP Net Income towards Common Stockholders figures stand at -$40.2 million (Q1 2026), -$46.9 million (Q4 2025), and -$32.0 million (Q3 2025).